Format

Send to

Choose Destination
Cancer Sci. 2019 May 8. doi: 10.1111/cas.14036. [Epub ahead of print]

Adipogenesis induces growth inhibition of dedifferentiated liposarcoma.

Kim YJ1, Yu DB1,2, Kim M1,2, Choi YL1,2,3.

Author information

1
Laboratory of Cancer Genomics and Molecular Pathology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
2
Department of Health Sciences and Technology, SAIHST, Sungkyunkwan University, Seoul, Korea.
3
Department of Pathology and Translational Genomics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.

Abstract

Well-differentiated liposarcoma (WDLPS) and dedifferentiated liposarcoma (DDLPS) are the most common types of liposarcoma. Although WDLPS and DDLPS patients receive intensive treatment including radical surgery and systemic therapy, their overall 5-year survival rates are 90% and 30%, respectively, indicating that DDLPS is clinically more aggressive. We examined whether adipogenic stimulation induces adipogenesis in human WDLPS/DDLPS cells by using dexamethasone, indomethacin, insulin, and 3-isobutyl-1-methylxanthine (IBMX), all putative medications or drugs. Functional in vitro experiments revealed that treatment with these four compounds induced adipogenic potency via the transcriptional and translational upregulation of genes related to the maintenance of stemness and adipogenic differentiation. Using in vivo xenograft models, we found that the induction of stemness and adipogenesis inhibited the tumorigenic potency of DDLPS. This study suggests a potential application of drug repositioning, in which adipogenesis-inducing compounds could be used to treat DDLPS patients in a clinical setting. This article is protected by copyright. All rights reserved.

KEYWORDS:

Adipogenesis; Dedifferentiated liposarcoma; Stemness; Well-differentiated liposarcoma; Xenograft

PMID:
31069877
DOI:
10.1111/cas.14036
Free full text

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center